1. Freese A., Swartz K.J., During M.J. and Martin J.B., 1990, Kynurenine metabolites of tryptophan: Implications for neurologic diseases,Neurology40: 691.
2. Fuchs D., Hausen A., Reibnegger G., Werner E.R., Dierich M.P. and Wachter H., 1988, Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection,Immunol
Today9: 150.
3. Fuchs D., Moller A.A., Reibnegger G., Stöckle E., Werner E.R., and Wachter H., 1990, Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/ psychiatric symptoms,J Acquir Immune
Defic Syndr3: 873.
4. Fuchs D., Forsman A., Hagberg L., et al., 1990, Immune activation and decreased tryptophan in patients with HIV-1 infection, J Interferon Res 10: 599.
5. Fuchs D., Werner E.R. and Wachter H., 1992, Soluble products of immune activation: Neopterin. In: Manual of Clinical Laboratory Immunology, 4th edition, R.R. Rose, E.C. deMacario, J.L. Fahey, H. Friedman and G.M. Penn, eds., American Society for Microbiology 251.